OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Core Viewpoint - OKYO Pharma Limited is advancing its lead clinical drug candidate, urcosimod, for the treatment of neuropathic corneal pain, a condition currently lacking FDA-approved therapies, and will present its development at an upcoming summit [1][2]. Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease, with its shares traded on the NASDAQ Capital Market [4]. Presentation Details - Dr. Gary S. Jacob, CEO of OKYO Pharma, will present on May 22, 2025, at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA, discussing the clinical development of urcosimod targeting CMKLR1 (ChemR23) for neuropathic corneal pain [2]. Neuropathic Corneal Pain (NCP) - NCP is characterized by severe pain and sensitivity in the eyes, face, or head, often resulting from nerve damage and inflammation, and is currently treated with limited success through off-label topical and systemic treatments [2]. Urcosimod Development - Urcosimod, a lipid-conjugated chemerin peptide agonist, is designed to enhance the residence time in the ocular environment and has shown anti-inflammatory and pain-reducing effects in preclinical models [3]. - The drug has demonstrated statistical significance in multiple endpoints in a Phase 2 trial for dry eye disease and is currently being evaluated in a Phase 2 trial for neuropathic corneal pain [3].